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This study examined whether patients with Hepatitis C virus (HCV) infection adhered to their physicians’
recommendation and HCV clinical guidelines for obtaining a regular liver function test (LFT), and whether highrisk behaviors are associated with behavioral adherence. A cross-sectional survey was administered to 101
eligible patients with HCV who were recruited from health centers in New Jersey and Washington, DC.
Adherence outcomes were defined as the patients’ self-report of two consecutive receipts of LFTs in accordance
with their physicians’ recommended interval or the clinical guidelines for a LFT within 3–6 months. 67.4% of
patients (66/98) reported a receipt of their physicians’ recommendation for a LFT. The rate of adherence to
physician recommendation was about 70% (46/66), however over 50% (52/101) of patients with HCV did not
obtain regular LFTs. 15.8% (16/101) of patients continued to use injection drugs. Patients who used injection
drugs had 0.87 (adjusted odds ratio (aOR) = 0.13, 95% confidence interval 0.03–0.59) times lower odds
adhering to their physician recommendation, relative to non-users. Patients with HIV co-infection had increased
odds of adhering to the clinical guidelines (odds ratio 3.41, 95% confidence interval 1.34–8.70) vs. patients who
did not report HIV co-infection. Additionally, patients who had received a physician’s recommendation had 7.21
times (95% confidence interval of 2.36–22.2) greater odds adhering to the clinical guidelines than those who had
not. Overall, promoting HCV patient-provider communication regarding regular LFTs and reduction of risk be
haviors is essential for preventing patients from HCV-related liver disease progression.

1. Introduction
Hepatitis C virus (HCV) infection is a significant public health
concern nationally and globally, with HCV-infection rates increasing
every year, over the last 10 years (National Progress Report 2020 Goal,
2020). The Center for Disease Control and Prevention (CDC) estimated
that 3.5 million people are infected with HCV in the United States
(Commentary | U.S., 2016; Denniston et al., 2014) and the World Health
Organization (WHO) has reported 185 million people are infected with

HCV, globally (Jefferies et al., 2018). Population-based research has
demonstrated that patients with HCV are at an increased risk of hepa
tocellular carcinoma (HCC) and advanced liver disease (Kanwal et al.,
2011). The slow progression from acute to chronic HCV can go unno
ticed, as acute HCV infection is asymptomatic in about 60–70% of pa
tients, the vast majority of whom come to clinical attention years later as
a result of screening tests, signs of cirrhosis, HCC, or liver failure (Viner
et al., 2015; Skolnik et al., 2019; Alter et al., 1992). The asymptomatic
progression of the disease contributes to the high mortality of persons
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2. Methods

with HCV (Toshikuni et al., 2014). Promoting awareness and prevention
of high-risk behaviors that further contribute to chronic liver disease
progression, together with clinical monitoring of liver injury and func
tion, are critical elements of managing the disease.
HCV infection is associated with several risk behaviors. Specifically,
alcohol consumption and drug use have been associated with the
accelerated progression of chronic liver disease for patients with HCV.
Research has shown the prevalence of chronic HCV infection was
significantly associated with both former and current excessive alcohol
consumption, after controlling for covariates (Taylor et al., 2016).
Additional studies revealed an association between HCV and HCC in
patients with alcoholic cirrhosis (Bruix et al., 1989; Fuster et al., 2016).
Two thirds of new HCV infections in western countries was associated
with injection drug use (IDU) (Fuster et al., 2016). Among individuals
17–59 years of age, drug use and high-risk sexual behaviors are addi
tional risk factors for acquiring HCV infection (Alter et al., 1999).
The American Association for the Study of Liver Diseases (AASLD)
and the Infectious Diseases Society for America (IDSA) guidelines for
HCV management have recommended that patients with HCV should
follow a continuum of care that includes monitoring before, during, and
after antiviral therapy. The AASLD-IDSA guidelines recommend
comprehensive cirrhosis management for patients with HCV, such as
receipt of regular liver function tests (LFTs) every three to six months to
reduce risks of further liver damage (Monitoring Patients Who Are
Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
| HCV Guidance, 2019). The AASLD-IDSA guidelines recommend the use
of LFTs, as their clinical utility is widely supported in the literature to
check liver function, liver diseases, and complications (Wai et al., 2003;
Sterling et al., 2006; Chou and Wasson, 2013). Few research studies
have examined whether patients with HCV receive follow-up care rec
ommendations from physicians and obtain regular LFTs consistent with
the AASLD-IDSA guidelines (Mathes et al., 2014).
To address these gaps in knowledge, we conducted an exploratory,
cross-sectional survey in a racially diverse sample of patients with HCV
to examine: 1) whether patients with HCV self-reported receiving and
adhering to their physician recommendations for regular liver function
tests (LFTs), and 2) whether these patients adhered to those recom
mendations for a continuum of care (e.g. timely LFTs) as recommended
by the AASLD-IDSA guidelines, and 3) what risk behavior factors, if any,
were associated with non-adherence. Results will inform clinical prac
tice and guide development of strategies to increase adherence to posttreatment liver testing in an effort to prevent HCV-related liver disease
progression.

2.1. Study population and recruitment
This study was approved by the Institutional Review Boards at
Georgetown University Medical Center (GUMC) and Hackensack Uni
versity Medical Center (HUMC). To ensure a diverse sample, we enrolled
eligible patients from health centers in both New Jersey (NJ) and
Metropolitan Washington, DC area. Eligible patients were: 1) patients
with HCV regardless of treatment status, 2) ages 18 years and older, and
3) English or Spanish speaking.
Eligible patients were recruited, consented, and surveyed by trained
bilingual research assistants either by telephone or in-person recruit
ment between January 2017 to April 2019 (Fig. 1). In the DC area, we
collaborated with the Practice-Based Research Network (PBRN) Capital
Area Primary Care Research Network (CAPRICORN). The HUMC
research team extended the patient enrollment with in-person recruit
ment from three community-based healthcare centers in northern New
Jersey and New York metropolitan areas. All of the healthcare centers in
the NJ sites served patients that were uninsured or underinsured, and
enrolled in Medicaid or Medicare. In contrast, the Georgetown sites were
primarily insured patients.
Each participant who completed the one-time survey received a $25
gift card as an incentive to compensate for their time and effort. Trained
research assistants administered the survey over the phone for both
sites, which took approximately 30–40 min to complete.
2.2. Data collection instrument
Trained bilingual interviewers administered the cross-sectional, selfreported survey by telephone to all participants.
2.2.1. Outcome variables
We assessed two study outcomes: 1) whether patients with HCV re
ported receiving and adhering to their physician’s recommendation
concerning LFT, and 2) whether patients adhered to the 2015 clinical
AASLD-IDSA guidelines, which recommend patients with HCV should
obtain a LFT every three to six months (Monitoring Patients Who Are
Starting HCV Treatment, Are on Treatment, or Have Completed Therapy
| HCV Guidance, 2019). Since this study was patient-focused, it did not
assess which clinical guidelines were used for follow-up care recom
mendations by our patients’ physicians. It is possible that physicians
may adopt different guidelines, however AASLD-IDSA guidelines are
widely recognized national guidelines for HCV treatment, monitoring,
and care – curated by a panel of hepatology and infectious disease

Fig. 1. Patient sample and recruitment methods.
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clinicians (Hepatitis C Guidance 2019 Update, 2019). As such, we
developed the following questionnaire to assess HCV patients’
adherence.
We asked patients to self-report: 1) whether they had received a
physician’s recommendation to obtain LFTs, 2) how often their physi
cian recommended them to obtain a LFT, 3) when was the most recent
time they had a LFT (e.g., 1–2 months, 3–6 moths, 7–12 months, or over
12 months), and 4) how many months ago they received a LFT, since
their most recent LFT. Patients were labeled as “adherent” to the timing
of follow-up testing when their LFTs were obtained either more
frequently or equal to the physician’s recommended interval. If the
patients were not able to answer the first two questions above, then the
patient was labeled as not receiving a physician’s recommendation. If
patients’ self-reported follow up LFTs were consistent to AASLD-IDSA
recommended frequency for LFTs of 3–6 months, then they were
labeled as “adherent” to the guidelines.

correct responses was summed to create the Hepatitis C knowledge score
in a 29-item survey, in which each correct item was scored 1 point. A
higher score demonstrated higher HCV knowledge.
2.3. Statistical analysis
Descriptive analysis was performed to calculate frequency, percent
age, mean, and standard deviation for all categorical or continuous
variables. Chi-square tests and Pearson correlations were used to
examine bivariate associations of demographic and other sample char
acteristics with risk behaviors and adherence outcomes. Independent
variables were considered potential predictors for the multivariate
model when their bivariate associations with the outcomes resulted in a
p-value of 0.20 or less. Next, we produced two logistic regression models
for each of the adherence outcomes: whether or not the patient reported
receiving their physician’s recommendations for LFTs, and whether or
not they received a follow-up LFT within the AASLD-IDSA guideline of
3–6 months. The final multivariate logistic regression models were
determined by using a backwards selection method in which the pre
dictor with the highest p-value was removed until all remaining pre
dictors’ p-values were 0.20 or less. All statistical analyses were
performed using SAS version 9.4.

2.2.2. Independent variables
Alcohol use behavior score was assessed using the validated WHO
Alcohol Use Disorder Identification Test (AUDIT) (WHO | AUDIT: The
Alcohol Use Disorders Identification Test, 2019; Saunders et al., 1993)
which is used to identify harmful patterns of alcohol consumption
through a 5-point Likert-type survey. Responses to the 10 alcohol
behavior questions were summed for each participant, and the mean
was taken. The total score ranged from 0 to 40, in which zero indicated
“no risk” and anything above 20 was considered to be “addiction likely.”
Alcohol use was measured using the question: “During the past 12
months, how often did you have a drink containing alcohol?” Alcohol
use was defined as having at least 1 drink in the past 12 months and no
alcohol use was defined as having zero drinks in the past 12 months.
Drug use questions were taken from the CDC’s National HIV Behav
ioral Surveillance (NHBS) of 2014–2016 (CDC’s Nation HIV Behavioral
Surveillence (NHBS), 2015). Example questions include: “Have you ever
in your life shot up or injected drugs other than those prescribed for you?
(yes/no)”; “When was the last time you injected any drug? (e.g., 30 days
ago)”; and “How many times have you injected any drug in the last
month?”. Ever used injection drugs was defined using the last question
and respondents were characterized into: 1) ever used injection drugs
(including patients who had ever injected or injected in the last month);
and 2) never used injection drugs.
Sexual history questions were from the CDC’s A Guide to Taking a
Sexual History (U.S. Department of Health and Human Services, 2011).
We assessed the number of sexual partners by asking about their sexual
history. Responses to the question, “In the past 12 months, how many
sexual partners have you had?” were categorized at “none to one part
ner” or “more than one partner”.
Other risky behavior questions were adapted from 2008 Blood Donor
History Questionnaire (BDHQ), (Blood Donor History Questionnaires,
2019). BDHQ survey questions measured other risky behaviors in the
past 12 months such as blood transfusion, transplant, come into contact
with someone else’s blood, accidental needle-stick, tattoo, ear/body
piercing, lived with someone with HCV or HBC, sexual contact with
anyone who has used needles for unprescribed drugs, been incarcerated,
or had hemodialysis. The total number of “yes” responses to each of
these questions for each participant was summed to calculate the risky
behavior score. Each yes to a question received 1 point and the total score
ranged from 0 to 10.
Demographic variables included age, gender, birthplace, education,
ethnicity, and race. Patient-reported comorbidity was based on the
Charlson Comorbidity Index (CCI) assessing the presence of 12 chronic
diseases (e.g., diabetics, hypertension, and arthritis). These comorbid
diseases were coded as present versus not present.
Hepatitis C Knowledge was assessed using a Hepatitis C questionnaire,
taken from HCV knowledge surveys developed by Sinclair and Trelor
(Sinclair, 2012; Treloar et al., 2012). Knowledge questions included risk
factors associated with HCV and how it spreads. The total number of

3. Results
3.1. Sample characteristics
The age of patients with HCV (N = 101) ranged between the ages of
18 and 80 (mean 56.75, SD: 11.0). Of the 101 patients, about 9% re
ported currently undergoing HCV treatment, 58% have completed
treatment, and 33% had not started treatment. The participant pool was
54.6% male and 45.5% female. In terms of education completion, 55.5%
completed less than high school, and 44.6% completed high school and
above. The majority of patients identified their race as Non-Hispanic
Black (63.4%), followed by 17.8% White, 10.9% Hispanic and 7.9%
identified as other.
Among all respondents, 55.5% were current smokers and 83.2% had
never injected drugs. Approximately 38% of patients had engaged in at
least one of the other risky behaviors (e.g., tattoo, blood transfusion,
unprotected sex with someone with HBV or HIV). Alcohol behavior
score was about 2.5, which demonstrated that on average patients
indicate no risk of having alcohol addiction (see Table 1).
3.2. Adherence rates
As shown in Table 2, 67.4% (66/98) of respondents reported that
their physicians recommended a future liver function testing regimen.
Among those who received a recommendation, 69.7% (46/66) received
a LFT consistent with their physician’s recommended interval. Among
those who did not report receiving a recommendation for a follow up
LFT by their physician (n = 32), about 13% received a LFT within 3–6
months, consistent with the AASLD-IDSA clinical guidelines. There were
no differences in the above outcomes by study site (data not shown).
3.3. Multivariate regression results
The multivariate logistic regression demonstrated that patients who
were persons who inject drugs (PWID), compared to non-users, had an
87% (adjusted odds ratio (aOR) = 0.13, 95% confidence interval (CI):
0.03–0.59) reduced odds for adhering to the physician recommenda
tions. In a subgroup analysis, PWID had 93% (aOR = 0.07, 95% CI:
0.02–0.26) lower odds to be currently on or have already completed
HCV treatment vs. those who did report ever using injection drugs (data
not shown). For adherence to AASLD guidelines, patients who reported
having HIV had an adjusted odds 3.41 (95% CI; 1.34–8.70) times greater
to receive a LFT within 3–6 months. Likewise, if the patient received a
3
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Table 1
Demographic and Behavioral Differences by Adherence Outcomes.
Variable

Physician Recommendation
No
Yes
Gender
Female
Male
Transgender
Education
<High School
≥High School
Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other
HIV-Coinfection
No
Yes
Hep A Vaccination
No
Yes
Hep B Vaccination
No
Yes
HCV Treatment
No
Yes
HCV Education
No
Yes
Alcohol use
None
≥1 in the last 12 months
Ever used injection drugs
No
Yes
Sexual partners
None to one
More than one
Smoker
Not Currently
Currently
Age++
Alcohol Use Behavior score++
Risky Behavior score++
Hepatitis C Knowledge score++

Adherence to physician recommendation+

Adherence to guidelines

Not Adherent
(n = 20)
n (%)

Not Adherent
(n = 52)
n (%)

Adherent
(n = 49)
n (%)

26 (50.0)
26 (50.0)

6 (13.0)
40 (87.0)

<0.001*

32 (32.7)
66 (67.4)

Adherent
(n = 46)
n (%)

p-value

p-value

Total
(N = 101)
n (%)

10 (50.0)
9 (45.0)
1 (5.0)

19 (43.2)
25 (56.8)
0

0.49

23 (44.2)
28 (53.9)
1 (1.9)

22 (45.8)
26 (54.8)
0

0.94

45 (45.0)
54 (54.0)
1 (1.0)

10 (50.0)
10 (50.0)

25 (55.6)
20 (44.4)

0.44

30 (57.70)
22 (42.3)

26 (53.1)
23 (46.9)

0.64

56 (55.5)
45 (44.6)

5 (25.0)
12 (60.0)
1 (5.0)
2 (10.0)

8 (17.8)
29 (64.4)
5 (11.1)
3 (6.7)

0.76

10 (19.2)
32 (61.5)
5 (9.6)
5 (9.6)

8 (16.3)
32 (65.3)
6 (12.2)
3 (6.1)

0.87

18 (17.8)
64 (63.4)
11 (10.9)
8 (7.9)

13 (65.0)
7 (35.0)

24 (53.3)
21 (46.7)

0.38

39 (75.0)
13 (25.0)

25 (51.0)
24 (49.0)

<0.001*

64 (63.4)
37 (36.6)

8 (44.4)
10 (55.6)

19 (46.3)
22 (53.7)

0.89

32 (65.3)
17 (34.7)

21 (47.7)
23 (52.3)

0.09

53 (57.0)
40 (43.0)

8 (47.1)
9 (52.9)

20 (45.5)
24 (54.6)

0.98

28 (59.6)
19 (40.4)

20 (42.6)
27 (57.5)

0.10

48 (51.1)
46 (48.9)

6 (31.6)
13 (68.4)

10 (22.7)
34 (77.3)

0.46

19 (38.0)
31 (62.0)

11 (23.4)
36 (76.6)

0.12

30 (30.9)
67 (69.1)

3 (15.8)
16 (84.2)

3 (6.8)
40 (93.2)

0.28

13 (25.5)
38 (74.5)

4 (8.5)
43 (91.5)

0.03*

17 (17.4)
81 (82.7)

9 (45.0)
11 (55.0)

25 (55.6)
20 (44.4)

0.43

27 (51.9)
25 (48.1)

26 (53.1)
23 (46.9)

0.91

53 (52.5)
48 (47.5)

13 (65.0)
7 (35.0)

42 (93.3)
3 (6.6)

<0.001*

38 (73.1)
14 (26.9)

46 (93.9)
3 (6.1)

0.01*

84 (83.2)
17 (16.8)

12 (60.0)
8 (40.0)

39 (86.7)
6 (13.3)

0.02*

36 (69.2)
16 (30.8)

43 (89.6)
5 (10.4)

0.01*

79 (79.0)
21 (21.0)

8 (40.0)
12 (60.0)
58.5 (11.3)
2.4 (4.2)
1.1 (1.3)
19.3 (3.3)

23 (51.1)
22 (48.9)
57.5 (10.8)
1.7 (3.4)
1.0 (1.4)
19.6 (3.2)

0.41

23 (44.2)
29 (55.8)
57.2 (10.6)
3.5 (4.9)
0.7 (1.1)
18.5 (4.0)

22 (44.9)
27 (55.1)
56.3 (11.5)
1.5 (3.2)
0.9 (1.4)
19.7 (3.3)

0.95

45 (44.6)
56 (55.5)
56.8 (11.0)
2.5 (4.3)
0.8 (1.3)
19.1 (3.7)

0.75
0.64
0.65
0.63

0.68
0.11
0.55
0.09

*

p-value < 0.05;
Sample size is smaller since only 66 out of 98 patients reported the receipt of a recommendation from their physician (yes/no), physician recommended time
period to get a LFT, and their last two completed LFTs;
++
For continuous variables, Mean (SD) was shown.
+

controlling for HIV co-infection and receipt of a physician’s recom
mendation (Table 2). The number of sexual partners was no longer
significant after controlling for injection drug use and alcohol use
behavior score. As such, the number of sexual partners was removed
from the final model during backward selection.

Table 2
Adjusted Odds Ratios for Adherence Outcomes (vs. Non-Adherence).
Outcomes

Variable

Adjusted
OR

95% CI

Physician
Adherence
Guideline
Adherence

Ever Used Injection Drugs (yes
vs no)
HIV-Coinfection (yes vs no)

0.13

Alcohol Use Behavior score
Receiving Physician
Recommendation

0.91
7.21

[0.03–0.59]
*
[1.34–8.70]
*
[0.74–1.12]
[2.36–22.2]
*

*

3.41

4. Discussion
The findings indicated that 67.4% of patients with HCV reported
receiving their physicians’ recommendation for obtaining regular LFTs.
Overall, 69.7% of patients with HCV, who received a physician recom
mendation, obtained regular LFTs. However, only 49% of the overall
sample obtained regular LFTs in adherence to the AASLD-IDSA followup care guidelines of 3–6 months. Those who ever used injection drugs
were less likely to adhere to physician recommendation to obtain LFTs
within the recommended interval. Patients with HIV/HCV co-infection

p < 0.05.

physician’s recommendation, they had an adjusted odds about 7 (95%
CI: 2.36–22.2) times greater to adhere to the clinical guidelines. Lastly,
alcohol use behavior score was not statistically significant after
4
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were more likely to adhere to the AASLD-IDSA guidelines. It is notable
that 36.6% of the sample were co-infected with HIV and about 16.8%
ever used injection drugs. While alcohol abstinence and Hepatitis A and
B vaccinations were not predictors of the adherence outcomes, they are
recommended practices for patients with HCV, according to the AASLDIDSA guidelines (Monitoring Patients Who Are Starting HCV Treatment,
Are on Treatment, or Have Completed Therapy | HCV Guidance, 2019).
However, 47.5% of the sample were alcohol users during the time of the
interviews and only about 43–48.9% of the sample reported receipt of
the vaccinations.
Our results suggest that routine inquiring of patients with HCV about
their receipt of LFTs and their involvement in risky behaviors, through
patient self-reports, may help monitor their risk of HCV re-infection and
receipt of recommended follow-up care. While most of our patients were
enrolled from primary care clinics and community health services, this
study did not adequately examine how patients with HCV communicate
with providers, nor did it examine factors affecting physician’s ability to
provide follow-up care recommendations for patients with HCV,
including HCV treatment. This is the first study that we are aware of
investigating adherence to follow-up recommendations for patients with
HCV in the U.S. and is largely exploratory in nature. Prior research has
mainly focused on screening and treatment (Skolnik et al., 2019; Mathes
et al., 2014; Edlin et al., 2005; Larrey et al., 2014). Further research is
needed on patients with HCV adherence to LFTs and the recommended
follow-up care.
Our study indicated that injection drug use was a key risky behavior
related to patients with HCV adherence to receipt of LFTs. 16.8% of our
patients reported the use of injection drugs. PWIDs oftentimes lack
stable housing, access to primary care services, and may have concur
rent psychiatric comorbidities (Edlin et al., 2005), making them less able
to receive routine care or manage psychiatric comorbid conditions in
order to follow recommended healthcare practices (i.e. making it to
appointments or following medical advice). Our findings showed the
PWIDs were less likely to comply with their physician recommendations
for regular LFTs (i.e. lower adherence) and AASLD-IDSA guidelines, and
engage in HCV treatment. The AASLD-IDSA guidelines recommend a
multidisciplinary setting to decrease future reinfection risks and manage
various social and psychiatric comorbidities (Monitoring Patients Who
Are Starting HCV Treatment, Are on Treatment, or Have Completed
Therapy | HCV Guidance, 2019). Several studies reported ways to
facilitate management of care such as using patient navigators to reduce
barriers in linkage and retention in care, providing on-site testing and
treatment (Ford et al., 2018; Coyle et al., 2019), or enhancing patients’
knowledge about HCV transmission (Jost et al., 2019). Patients’
adherence to testing - consistent with AASLD-IDSA guidelines - may also
be largely attributed to their health provider’s awareness of up-to-date
guidelines and routine testing procedures; but patient recall of testing
may also be variable. Addressing barriers to care and patient education
is critical to ensure effective treatment and management of HCV by
providers (Ford et al., 2018; Jost et al., 2019).
Among the variables examined as possible predictors for adherence
to AASLD-IDSA guidelines, HIV-coinfection and receiving a physician’s
recommendation demonstrated strong associations with adherence to
the guidelines. Patients with HIV/HCV co-infection had 2.36 times
increased odds of adhering to the guidelines. Nationally, about 21–25%
of HIV individuals tested positive for HCV (Garg et al., 2014; Maier and
Wu, 2002), which is similar to the proportion of our study participants
(26.7%). Liver disease progresses more rapidly in patients with HIV/
HCV coinfection (Maier and Wu, 2002; Solà et al., 2006) and they
experience more liver-related morbidity and overall mortality,
compared to patients mono-infected with HCV (Re et al., 2014; Metaanalysis: Increased Mortality Associated With Hepatitis C in HIVinfected Persons Is Unrelated to HIV Disease Progression - PubMed,
2020). As a unique population, established in the AASLD-IDSA guide
lines, follow-up testing may be a routine part of their HIV-associated
medical care, which necessitates routine lab testing that often includes

blood panels containing LFTs. This may explain why they get LFTs more
frequently compared to those who were not co-infected with HIV. It is
unknown whether those infected with only HCV perceive lower risk for
re-infection or other liver-related diseases, which may deter them from
following their physician recommendation. Investigating and strength
ening patient-provider communication on injection drug use among
patients with HCV are particularly needed, as it was the only significant
predictor found in this study to reduce adherence to physician
recommendations.
4.1. Limitations
This study was limited to the selected DC and NJ clinics and may not
represent persons with HCV in those regions as a whole, nor in other
cities or states. Second, the sample size was relatively modest. The
observed associations will need to be confirmed in larger populationbased research. In addition, we did not look at outcomes related to the
development of HCC or cirrhosis, and it is unclear whether adherence to
the recommended follow-up care will prevent persons with HCV from
developing cirrhosis or liver cancer. This study was also solely based on
patient recall, which may largely affect whether patients accurately
reported physician recommendations, and subsequent liver function
testing and time of completion; although, patients’ self-report has pre
viously been used to understand health care utilization and a patient’s
health behaviors (Short et al., 2009). This study also did not record
which clinical guidelines were utilized by our patients’ physicians.
Therefore, we do not have data from physicians to support whether they
follow AASLD-IDSA guidelines. Future prospective, longitudinal
research will be needed to examine the effects of adherence to clinical
recommendations and liver-related morbidity and mortality, as well as
the use of patient medical records to record physician liver function
testing referrals and test dates for accuracy.
4.2. Clinical implications and recommendations
Primary care providers (PCPs) are essential partners in delivering
evidence-based care and services for patients with HCV, particularly for
at risk patients involved in risky behavior (i.e. injection drug use), as
well as monitor important disease markers such as liver function tests
(Artenie et al., 2014). As a first point of contact for patients with HCV,
PCPs can provide additional information on how to avoid high-risk be
haviors, especially among people who inject drugs (PWID) and those
with HIV/HCV coinfection. Those that continue to be involved in highrisk behaviors, despite their HCV diagnosis, may benefit from physician
education and recommendations. Our findings showed that a substantial
number of patients (32.7%, 22/98) did not report receiving a physician
recommendation for LFT, but physician recommendation was a strong
predictor of patient adherence to regular LFTs. Other research also
showed that PWIDs with access to a PCP are more likely to receive re
ferrals to a liver clinic (Artenie et al., 2014). Additionally, our study
indicated that the rates of Hep B and A vaccination were moderate,
despite being among the recommended vaccinations in the AASLD-IDSA
guidelines. Being regularly tested with LFTs can provide important
surveillance for serious complications such as HCC and cirrhosis (Viner
et al., 2015; Skolnik et al., 2019; Alter et al., 1992). Disseminating HCV
care guidelines and increasing PCPs awareness of AASLD-IDSA’s rec
ommended vaccinations can help facilitate adherence to follow-up ap
pointments for LFTs and prescription of Hep A/B vaccinations.
5. Conclusions
HCV-infections are increasing in the U.S. (National Progress Report
2020 Goal, 2020), largely due to the rise in injection drug use as a result
of the opioid epidemic (Commentary | U.S., 2016; Jost et al., 2019;
Zibbell et al., 2018). These cross-sectional study findings are preliminary
but shed light on the relationship between continued use of injection
5
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drugs and adherence to recommended practice in risk monitoring. This
study suggests that prioritizing patient education about HCV and risk
behaviors, and PCP recommendations will need to be strengthened in
public health interventions (e.g., educational campaigns), as well as
patient-provider communication regarding follow-up care guidelines.
Additional research is needed to understand the long-term health out
comes associated with such adherence, which may be helpful in
reducing advanced liver disease.
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